O
Olivia Guillin
Researcher at Claude Bernard University Lyon 1
Publications - 5
Citations - 352
Olivia Guillin is an academic researcher from Claude Bernard University Lyon 1. The author has contributed to research in topics: Selenocysteine & Selenoprotein. The author has an hindex of 3, co-authored 3 publications receiving 176 citations.
Papers
More filters
Journal ArticleDOI
Selenium, Selenoproteins and Viral Infection
TL;DR: The formal identification of viral selenoproteins in the genome of molluscum contagiosum and fowlpox viruses demonstrated the importance of selenocsteine in viral cycle.
Journal ArticleDOI
Translational control of coronaviruses.
Sylvain de Breyne,Caroline Vindry,Olivia Guillin,Lionel Condé,Fabrice Mure,Henri Gruffat,Laurent Chavatte,Théophile Ohlmann +7 more
TL;DR: A review of how coronaviruses have developed remarkable strategies to hijack the host translational machinery in order to favor viral protein production and the role of viral proteins and RNAs in this process is highlighted.
Journal ArticleDOI
A Versatile Strategy to Reduce UGA-Selenocysteine Recoding Efficiency of the Ribosome Using CRISPR-Cas9-Viral-Like-Particles Targeting Selenocysteine-tRNA[Ser]Sec Gene.
TL;DR: A recently developed CRISPR strategy based on murine leukemia virus-like particles loaded with Cas9-sgRNA ribonucleoproteins to inactivate the Sec-tRNA[Ser]Sec gene in human cell lines is used and this caused a robust reduction of selenoprotein expression.
Journal ArticleDOI
Interplay between Selenium, Selenoproteins and HIV-1 Replication in Human CD4 T-Lymphocytes
TL;DR: It was shown that selenium had no significant effect on HIV-1 protein production nor on infectivity, but slightly reduced the percentage of infected cells in a Jurkat cell line and isolated primary CD4 T cells, and in response to HIV- 1 infection, the selenoproteome was slightly altered.
Journal ArticleDOI
A homozygous mutation in the human selenocysteine tRNA gene impairs UGA recoding activity and selenoproteome regulation by selenium.
Caroline Vindry,Olivia Guillin,Philippe Wolff,Paul Marie,Franck Mortreux,Philippe E. Mangeot,Théophile Ohlmann,Laurent Chavatte +7 more
TL;DR: In this paper , the authors used CRISPR/Cas9 technology to engineer homozygous and heterozygous mutant human cells, which were then compared with the parental cell lines.